Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Core Insights - Editas Medicine is a pure in-vivo focused CRISPR editing company with proprietary technologies for gene editing and delivery [4][5] - The company has validated its editing machinery in humans, utilizing both AsCas12a and Cas9 enzymes [4][5] - Editas is currently focused on two lead assets, particularly targeting hematopoietic stem cells [5] Company Overview - The company has a robust targeting LNP delivery system that provides flexibility and optionality in its operations [4] - Editas aims to create value over the next 12 to 24 months by leveraging its strengths and addressing challenges [4]